TGA Sues BioV8 for Unlawful Peptide Advertising
The TGA has commenced Federal Court proceedings against BioV8 and its directors for allegedly unlawfully advertising prescription-only peptides, including BPC-157 and CJC-1295.
The Therapeutic Goods Administration (TGA) has escalated its enforcement actions in the peptide industry by commencing Federal Court proceedings against A.C.N. 641 483 703 Pty Ltd (in liquidation), formerly known as BioV8 Pty Ltd, and its former directors, Edward McGill and Nicholas Austin. The TGA alleges that BioV8 engaged in the unlawful advertising of prescription-only therapeutic goods, specifically peptides, in direct contravention of the Therapeutic Goods Act 1989 (Cth) (the Act).
According to the TGA’s allegations, BioV8 unlawfully advertised peptides such as BPC-157, CJC-1295, and GHRP-6 on its website and various social media platforms between June 2024 and July 2025. A significant aspect of the TGA’s case revolves around BioV8 allegedly promoting these peptides for the treatment of serious diseases, conditions, and disorders, including but not limited to cancer, HIV/AIDS, and mental illnesses. Such claims are classified as restricted or prohibited representations under Australian therapeutic goods advertising regulations and require specific TGA approval or permission, which BioV8 reportedly lacked.
The TGA further alleges that Mr. McGill and Mr. Austin actively aided, abetted, counselled, or procured this unlawful advertising by BioV8. The regulatory body is seeking declarations and pecuniary penalties against both the company and its former directors. The proceedings against the company are subject to a grant of leave by the Federal Court, given BioV8 is now in liquidation.
This legal action underscores the TGA’s unwavering commitment to regulating the therapeutic goods landscape in Australia. Professor Anthony Lawler, Deputy Secretary of the Department of Health, Disability and Ageing and head of the TGA, reinforced this stance, stating, “Businesses and individuals are reminded that the TGA will take legal action against all entities unlawfully operating in the peptide industry. This includes health practitioners, compounding pharmacies, social media influencers and telehealth clinics where we identify unlawful advertising of peptides”.
Professor Lawler also highlighted the inherent dangers of unapproved peptides, noting they “can pose serious risks to Australian consumers.” He emphasised the responsibility of businesses to ensure strict adherence to Australia’s therapeutic goods framework. Unapproved therapeutic goods, by definition, have not been assessed by the TGA for safety, quality, or effectiveness and are not listed on the Australian Register of Therapeutic Goods (ARTG). Their unverified nature presents potential health risks to consumers.
The TGA has recently broadened its enforcement focus to include unapproved peptide products, responding to a surge in unlawful importation, supply, and advertising activities. This proactive measure aims to mitigate the potential risks to consumer safety posed by such products. Businesses and individuals found engaging in unlawful conduct involving peptide products should anticipate heightened compliance actions from the TGA.
This case serves as a critical reminder to all stakeholders in the peptide space about the strict regulatory environment in Australia. It reinforces the necessity of understanding and complying with the Therapeutic Goods Act 1989 to avoid significant legal and financial repercussions.
For educational purposes only. This content is informational and reflects publicly reported developments. It is not legal, medical, or regulatory advice. Consult a qualified professional for compliance questions.